Enveric Biosciences stock analysis
Enveric Biosciences (SLZ0) Stock Price & Analysis
SLZ0 Stock Chart & Stats
- Day’s Range
- EUR 4.67 - EUR 4.79
- 52-Week Range
- EUR 4.67 - EUR 4.79
- Previous Close
- EUR 4.67
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 6.15M
- Enterprise Value
- EUR 1.05M
- Total Cash (Recent Filing)
- EUR 5.61M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- -1.11
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
The absence of debt limits fixed financial obligations and reduces solvency and refinancing pressure while the company funds drug discovery and development. This gives management more flexibility than leveraged peers, although it does not eliminate the need for future capital.
Improved Equity Base
Growth in equity provides a larger capital cushion for ongoing research and development than the company had in 2024. A stronger equity base can improve financial resilience, though the cushion remains modest relative to continuing losses and cash requirements.
Lower Operating Losses
Improving operating losses indicate some progress toward controlling the cost base as the development platform advances. If sustained, this trend could extend the company’s financial runway and reduce the amount of capital required to support future clinical and preclinical work.
Bears Say
No Commercial Revenue
Zero reported revenue shows that Enveric has not yet reached meaningful commercial scale or established a self-funding product base. Its financial outlook therefore remains dependent on successful development and eventual commercialization of drug candidates rather than current operating sales.
Persistent Cash Burn
Persistent negative operating and free cash flow means research activities continue to consume cash rather than fund themselves. This structurally increases reliance on external financing and leaves less flexibility to absorb development delays, sustain trials, or advance multiple candidates.
Large Losses And Thin Capital
The sizable ongoing loss relative to the company’s equity base highlights limited financial scale and weak current returns on invested capital. Continued losses can erode the capital cushion over time and increase the importance of obtaining funding to maintain development operations.
Enveric Biosciences News
SLZ0 FAQ
What was Enveric Biosciences’s price range in the past 12 months?
What is Enveric Biosciences’s market cap?
When is Enveric Biosciences’s upcoming earnings report date?
How were Enveric Biosciences’s earnings last quarter?
Is Enveric Biosciences overvalued?
Does Enveric Biosciences pay dividends?
What is Enveric Biosciences’s EPS estimate?
How many shares outstanding does Enveric Biosciences have?
What happened to Enveric Biosciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Enveric Biosciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joseph Edward Tucker
- Employees
- 6
- Website
- www.enveric.com
- Address
- 245 First Street, Cambridge, MA, 02142, US
Enveric Biosciences (SLZ0) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 4 |
| Technical Analysis | 2 | 1 | 0 |
| Moving Averages | 6 | 2 | 4 |












